Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
How do you approach distinguishing between primary and secondary FSGS in a patient who is PLA2R negative?
Related Questions
Do you modify the albumin level below which you would prophylactically anticoagulate a pregnant patient with nephrotic-range proteinuria, given that hypoalbuminemia is expected in pregnancy?
What factors do you consider when deciding to treat IgA nephropathy with immunosuppression in a patient with cirrhosis, given the possibility that IgA nephropathy could be secondary to cirrhosis?
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
Would you consider initiating eculizumab without plasmapheresis as initial therapy for a patient with renal TMA who has a low suspicion of TTP based on a scoring algorithm?
Would you pursue a kidney biopsy in a patient with stable stage 1 AKI, bland urine sediment, and a positive MPO titer without systemic signs of vasculitis?
How do you counsel patients who are found to have a carrier mutation in a single high-risk APOL1 allele?
How often do you check fibrinogen levels and when do you administer FFP for patients with AKI requiring plasma exchange?
What clinical criteria do you use to decide between antivirals, rituximab, plasmapheresis, or a combination therapy for treating hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis?
Would you consider using a combination regimen of rituximab, low-dose cyclophosphamide, and steroids to improve complete remission rates in patient with PLA2R-positive membranous nephropathy?
How would you approach the treatment of crescentic fibrillary glomerulonephritis?
